1. Yancy, CW, Jessup, M, Bozkurt, B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240–e327.
Google Scholar | Crossref | Medline | ISI2. Shah, KS, Xu, H, Matsouaka, RA, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol. 2017;70(20):2476–2486.
Google Scholar | Crossref | Medline3. Ziaeian, B, Fonarow, GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016;13(6):368–378.
Google Scholar | Crossref | Medline4. Oeing, CU, Tschöpe, C, Pieske, B. The new ESC guidelines for acute and chronic heart failure 2016 [in German]. Herz. 2016;41(8):655–663.
Google Scholar | Crossref | Medline5. Ponikowski, P, Voors, AA, Anker, SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–2200.
Google Scholar | Crossref | Medline | ISI6. McMurray, JJV, Solomon, SD, Inzucchi, SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
Google Scholar | Crossref | Medline7. Armstrong, PW, Pieske, B, Anstrom, KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382(20):1883–1893.
Google Scholar | Crossref | Medline8. Sauer, AJ, Cole, R, Jensen, BC, et al. Practical guidance on the use of sacubitril/valsartan for heart failure. Heart Fail Rev. 2019;24(2):167–176.
Google Scholar | Crossref | Medline9. Li, B, Zhao, Y, Yin, B, et al. Safety of the neprilysin/renin-angiotensin system inhibitor LCZ696. Oncotarget. 2017;8(47):83323–83333.
Google Scholar | Crossref | Medline10. Potter, LR, Yoder, AR, Flora, DR, Antos, LK, Dickey, DM. Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol. 2009;(191):341–366.
Google Scholar | Crossref | Medline11. Stoupakis, G, Klapholz, M. Natriuretic peptides: biochemistry, physiology, and therapeutic role in heart failure. Heart Dis (Hagerstown, Md). 2003;5(3):215–223.
Google Scholar | Crossref | Medline12. Hubers, SA, Brown, NJ. Combined angiotensin receptor antagonism and neprilysin inhibition. Circulation. 2016;133(11):1115–1124.
Google Scholar | Crossref | Medline13. Singh, JSS, Burrell, LM, Cherif, M, Squire, IB, Clark, AL, Lang, CC. Sacubitril/valsartan: beyond natriuretic peptides. Heart (British Cardiac Society). 2017;103(20):1569–1577.
Google Scholar | Crossref | Medline14. Richards, AM, Wittert, GA, Espiner, EA, Yandle, TG, Ikram, H, Frampton, C. Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers. Circ Res. 1992;71(6):1501–1507.
Google Scholar | Crossref | Medline15. Packer, M, Califf, RM, Konstam, MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002;106(8):920–926.
Google Scholar | Crossref | Medline | ISI16. Liu, B, Zhang, R, Wei, S, et al. ALDH2 protects against alcoholic cardiomyopathy through a mechanism involving the p38 MAPK/CREB pathway and local renin-angiotensin system inhibition in cardiomyocytes. Int J Cardiol. 2018;257:150–159.
Google Scholar | Crossref | Medline17. Sayer, G, Bhat, G. The renin-angiotensin-aldosterone system and heart failure. Cardiol Clin. 2014;32(1):21–32, vii.
Google Scholar | Crossref | Medline | ISI18. van Thiel, BS, van der Pluijm, I, te Riet, L, et al. The renin-angiotensin system and its involvement in vascular disease. Eur J Pharmacol. 2015;763(Pt A):3–14.
Google Scholar | Crossref | Medline19. Puljak, L, Ramic, I, Arriola Naharro, C, et al. Cochrane risk of bias tool was used inadequately in the majority of non-cochrane systematic reviews. J Clin Epidemiol. 2020;123:114–119.
Google Scholar | Crossref | Medline20. McMurray, JJ, Packer, M, Desai, AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.
Google Scholar | Crossref | Medline | ISI21. Velazquez, EJ, Morrow, DA, DeVore, AD, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380(6):539–548.
Google Scholar | Crossref | Medline22. Morrow, DA, Velazquez, EJ, DeVore, AD, et al. Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril/valsartan or enalapril in the PIONEER-HF Trial. Circulation. 2019;139(19):2285–2288.
Google Scholar | Crossref | Medline23. Tan, NY, Sangaralingham, LR, Sangaralingham, SJ, Yao, X, Shah, ND, Dunlay, SM. Comparative effectiveness of sacubitril-valsartan versus ACE/ARB therapy in heart failure with reduced ejection fraction. JACC Heart Fail. 2020;8(1):43–54.
Google Scholar | Crossref | Medline24. Vaduganathan, M, Claggett, BL, Jhund, PS, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet (London, England). 2020;396(10244):121–128.
Google Scholar | Crossref | Medline25. Nielsen, EE, Feinberg, JB, Bu, FL, et al. Beneficial and harmful effects of sacubitril/valsartan in patients with heart failure: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Open Heart. 2020;7(2):e001294.
Google Scholar | Crossref | Medline26. Solomon, SD, Claggett, B, McMurray, JJ, Hernandez, AF, Fonarow, GC. Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis. Eur J Heart Fail. 2016;18(10):1238–1243.
Google Scholar | Crossref | Medline27. Solomon, SD, McMurray, JJV, Anand, IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609–1620.
Google Scholar | Crossref | Medline28. Salah, HM, Fudim, M, Al’Aref, SJ, et al. Meta-analysis of efficacy of sacubitril/valsartan in heart failure with preserved ejection fraction. Am J Cardiol. 2021;145:165–168.
Google Scholar | Crossref | Medline29. Nie, D, Xiong, B, Qian, J, et al. The effect of sacubitril-valsartan in heart failure patients with mid-range and preserved ejection fraction: a meta-analysis. Heart Lung Circ. 2021;30(5):683–691.
Google Scholar | Crossref | Medline30. Solomon, SD, Vaduganathan, M, Claggett, BL, et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation. 2020;141(5):352–361.
Google Scholar | Crossref | Medline31. Thomas, L, Abhayaratna, WP. Left atrial reverse remodeling: mechanisms, evaluation, and clinical significance. JACC Cardiovasc Imaging. 2017;10(1):65–77.
Google Scholar | Crossref | Medline32. Kang, DH, Park, SJ, Shin, SH, et al. Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation. Circulation. 2019;139(11):1354–1365.
Google Scholar | Crossref | Medline33. Januzzi, JL, Prescott, MF, Butler, J, et al. Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA. 2019;322(11):1–11.
Google Scholar | Crossref34. Wang, Y, Zhou, R, Lu, C, et al. Effects of the angiotensin-receptor neprilysin inhibitor on cardiac reverse remodeling: meta-analysis. J Am Heart Assoc. 2019;8(13):e012272.
Google Scholar | Crossref | Medline35. Solomon, SD, Zile, M, Pieske, B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet (London, England). 2012;380(9851):1387–1395.
Google Scholar | Crossref | Medline | ISI36. Dini, FL, Carluccio, E, Simioniuc, A, et al. Right ventricular recovery during follow-up is associated with improved survival in patients with chronic heart failure with reduced ejection fraction. Eur J Heart Fail. 2016;18:1462–1471.
Google Scholar | Crossref | Medline37. Correale, M, Mallardi, A, Mazzeo, P, et al. Sacubitril/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: the Daunia Heart Failure Registry. Int J Cardiol Heart Vasc. 2020;27:100486.
Google Scholar | Crossref | Medline38. Hari, KJ, Nguyen, TP, Soliman, EZ. Relationship between P-wave duration and the risk of atrial fibrillation. Expert Rev Cardiovasc Ther. 2018;16(11):837–843.
Google Scholar | Crossref | Medline39. Okutucu, S, Fatihoglu, SG, Sabanoglu, C, et al. Effects of angiotensin receptor neprilysin inhibition on P-wave dispersion in heart failure with reduced ejection fraction. Herz. 2021;46(suppl 1):69–74.
Google Scholar | Crossref | Medline40. De Vecchis, R, Paccone, A, Di Maio, M. Favorable effects of sacubitril/valsartan on the peak atrial longitudinal strain in patients with chronic heart failure and a history of one or more episodes of atrial fibrillation: a retrospective cohort study. J Clin Med Res. 2020;12(2):100–107.
Google Scholar | Crossref | Medline41. Chalikias, G, Kikas, P, Thomaidis, A, et al. Effect of sacubitril/valsartan on circulating catecholamine levels during a 6-month follow-up in heart failure patients. Timeo Danaos et dona ferentes? Acta Cardiologica. 2020;76(4):396–401.
Google Scholar | Crossref | Medline42. Ibrahim, NE, McCarthy, CP, Shrestha, S, et al. Effect of neprilysin inhibition on various natriuretic peptide assays. J Am Coll Cardiol. 2019;73(11):1273–1284.
Google Scholar | Crossref | Medline43. Garin, O, Herdman, M, Vilagut, G, et al. Assessing health-related quality of life in patients with heart failure: a systematic, standardized comparison of available measures. Heart Fail Rev. 2014;19(3):359–367.
Google Scholar | Crossref | Medline44. Khariton, Y, Fonarow, GC, Arnold, SV, et al. Association between sacubitril/valsartan initiation and health status outcomes in heart failure with reduced ejection fraction. JACC Heart Fail. 2019;7(11):933–941.
Google Scholar | Crossref | Medline45. Thomas, M, Khariton, Y, Fonarow, GC, et al. Association between sacubitril/valsartan initiation and real-world health status trajectories over 18 months in heart failure with reduced ejection fraction. ESC Heart Fail. 2021;8(4):2670–2678.
Google Scholar | Crossref | Medline46. Du, H, Wonggom, P, Tongpeth, J, et al. Six-minute walk test for assessing physical functional capacity in chronic heart failure. Curr Heart Fail Rep. 2017;14(2):158–166.
Google Scholar | Crossref | Medline47. Beltrán, P, Palau, P, Domínguez, E, et al. Sacubitril/valsartan and short-term changes in the 6-minute walk test: a pil